Is Revolutionary Balloon Catheter Therapy the Future of Heart Attack Treatment?

• Intratech Medical’s novel Booster™ balloon catheter therapy could revolutionize the treatment of acute myocardial infarction (AMI).
• This Israeli-based startup is developing a unique solution aimed at reducing infarct size, improving patient outcomes, and decreasing related healthcare costs.
• The Booster spiral balloon catheter has a proprietary design which elevates pressure without compromising blood outflow, thereby improving oxygen delivery to the ischemic myocardium.
• The device doesn’t require expensive console monitoring and is simple to use, similar to any angioplasty balloon.

Every year, a staggering number of people worldwide—approximately 16 million—experience a heart attack. Over a third of these patients will have an acute myocardial infarction (AMI) that requires immediate revascularization of the clogged artery. This is where Israeli-based startup Intratech Medical steps in. They are developing a revolutionary device: the Booster balloon catheter therapy, designed to greatly improve the clinical outcomes for AMI patients.

The Booster balloon targets the treatment of the area around the infarcted heart muscle. This area can grow and convert into scar tissue even after successful revascularization, leading to a higher risk of heart failure. The Booster catheter is designed to mitigate this risk by reducing the infarct area and, ultimately, the impact on patients’ lives.

What differentiates Intratech Medical is their proprietary and patented Booster spiral balloon catheter. Unlike other technologies on the market, it does not require an expensive console to monitor the operation of the balloon and uses standard catheterization laboratory equipment. Its design is intuitive and simple, comparable to any angioplasty balloon, eliminating the need for dedicated personnel.

This new therapy increases the pressure in the heart venules and capillaries, improving oxygen delivery to the ischemic myocardium, without compromising the blood outflow. The result is a reduction in the infarct area, leading to improved patient outcomes and a decrease in related health care costs.

The future of Intratech Medical is promising, with exciting pre-clinical results leading up to its First-In-Human clinical study launching in Q3 2021. Securing a major investment from a key strategic corporation in the interventional cardiology field bolsters their potential in reshaping AMI treatment. With patents granted in multiple regions including the US, Europe, and China, Intratech is in a strong position to move forward in its industry.